BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it will report its second quarter 2011 financial results on Thursday, August 4, 2011, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
LIVE access on Thursday, August 4, 2011
1:30 p.m. Pacific Time (PT) / 4:30 p.m. Eastern Time (ET)
- Telephone (877) 941-2333 (domestic) or (480) 629-9773 (international); conference ID 4459836
- Webcast available at http://www.seattlegenetics.com in the Investors and News section
REPLAY access
- Telephone replay will be available beginning at approximately 3:30 p.m. PT on Thursday, August 4, 2011, through 3:30 p.m. PT on Monday, August 8, 2011, by calling (800) 406-7325 (domestic) or (303) 590-3030 (international); conference ID 4459836
- Webcast replay will be available on the Seattle Genetics website at http://www.seattlegenetics.com in the Investors and News section
About Seattle Genetics
Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The U.S. Food and Drug Administration has granted priority review to Biologics License Applications for its lead product candidate, ADCETRIS™, for the treatment of relapsed or refractory Hodgkin lymphoma and relapsed or refractory systemic anaplastic large cell lymphoma, with a PDUFA date of August 30, 2011. ADCETRIS is being developed in collaboration with Millennium: The Takeda Oncology Company. In addition, Seattle Genetics has five other clinical-stage programs: SGN-75, ASG-5ME, ASG-22ME, dacetuzumab (SGN-40) and SGN-70. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Abbott, Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC co-development agreements with Agensys, an affiliate of Astellas, and Genmab. More information can be found at http://www.seattlegenetics.com.
Certain of the statements made in this press release are forward looking, such as those, among others, relating to the company's expectations for regulatory approval and commercial launch of ADCETRIS. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks that data from our pivotal Hodgkin lymphoma trial and phase II systemic ALCL trial of ADCETRIS will not support marketing approval for the submitted indications. More information about the risks and uncertainties faced by Seattle Genetics is contained in the company's 10-Q for the quarter ended March 31, 2011 filed with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT:
Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
[email protected]
KEYWORDS: United States North America Washington
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical
MEDIA:
| Logo |